NEUROSENSE THERAPEUTICS LTD
NRSN · NASDAQ
更新於 2026-10-14 09:31:18
- 今日最高
- $3.78
- 今日最低
- $3.36
%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23150%3B%26%23135%3B%26%23230%3B%26%23161%3B%26%23163%3B%26%23230%3B%26%23154%3B%26%23151%3B%26%23232%3B%26%23167%3B%26%23146%3B%22%20d%3D%22M48.3363%2013.4132H60.2082L46.795%205.72205e-06V11.8719C46.795%2012.7231%2047.4851%2013.4132%2048.3363%2013.4132Z%22%20fill%3D%22var(--fill-0%2C%20%23474741)%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23148%3B%26%23190%3B%26%23229%3B%26%23164%3B%26%23167%3B%26%23233%3B%26%23149%3B%26%23156%3B%22%20fill-rule%3D%22evenodd%22%20clip-rule%3D%22evenodd%22%20d%3D%22M11.3812%2020.3725C16.7977%2014.9559%2025.5803%2014.9559%2030.9969%2020.3725C36.413%2025.789%2036.4131%2034.5707%2030.9969%2039.9872C26.0109%2044.973%2018.1729%2045.3699%2012.7335%2041.1769L2.54298%2051.3684L0%2048.8254L10.1915%2038.6329C5.99993%2033.1937%206.39609%2025.3579%2011.3812%2020.3725ZM28.4539%2022.9155C24.4418%2018.9033%2017.9363%2018.9033%2013.9241%2022.9155C9.91245%2026.9275%209.91241%2033.4322%2013.9241%2037.4442C17.9362%2041.4562%2024.4418%2041.4562%2028.4539%2037.4442C32.4656%2033.4322%2032.4656%2026.9275%2028.4539%2022.9155Z%22%20fill%3D%22var(--fill-0%2C%20%235D5D56)%22%2F%3E%0A%3C%2Fg%3E%0A%20%20%3C%2Fsvg%3E%0A%3C%2Fsvg%3E%0A)
K線圖趨勢，實際資料以交易頁為準
關鍵數據
- 昨天開盤價
- $3.66
- 昨天收盤價
- $3.48
- 成交量
- 7.42K
- 市值
- $6.6M
- 市盈率（P/E）
- --
- 每股收益（EPS）
- $-10.78
昨天價格區間
52週價格區間
公司概況
- 板塊
- HEALTHCARE
- 行業
- Biotechnology
- 子行業
- BIOTECHNOLOGY
- 總部
- BUILDING B, HERZLIYA, ISRAEL, 4672562
- 國家
- IL
- 上市日期
- 2021-12-09
- 財年截止
- December
- 流通股數
- 35.35M
- CIK
- 0001875091
Neurosense Therapeutics Ltd (NRSN) is a clinical-stage biotechnology firm dedicated to innovating treatments for neurodegenerative diseases, with a particular emphasis on Parkinson's disease. The company is advancing a diverse pipeline of therapeutic candidates through pivotal clinical trials, addressing critical unmet needs in neurology. With a seasoned management team and strategic partnerships, Neurosense is poised to develop groundbreaking therapies that not only enhance patient outcomes but also bolster its competitive position in the biopharmaceutical sector.
財務指標
營業收入
2025-12-31
--
2025-09-30
--
2025-06-30
--
2025-03-31
--
營業支出
2025-12-31
$3.19M
2025-09-30
$3.19M
2025-06-30
$2.34M
2025-03-31
$2.34M
淨利潤
2025-12-31
-$3.2M
2025-09-30
-$3.2M
2025-06-30
-$2.35M
2025-03-31
-$2.35M
淨利潤率
2025-12-31
--
2025-09-30
--
2025-06-30
--
2025-03-31
--
每股收益
2025-12-31
$0.00
2025-09-30
$-0.04
2025-06-30
$-0.19
2025-03-31
$-0.06
息稅折舊攤銷前利潤
2025-12-31
-$3.19M
2025-09-30
-$3.19M
2025-06-30
-$2.34M
2025-03-31
-$2.34M
有效稅率
2025-12-31
--
2025-09-30
--
2025-06-30
--
2025-03-31
--
| 項目 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
| 營業收入 | -- | -- | -- | -- |
| 營業支出 | $3.19M | $3.19M | $2.34M | $2.34M |
| 淨利潤 | -$3.2M | -$3.2M | -$2.35M | -$2.35M |
| 淨利潤率 | -- | -- | -- | -- |
| 每股收益 | $0.00 | $-0.04 | $-0.19 | $-0.06 |
| 息稅折舊攤銷前利潤 | -$3.19M | -$3.19M | -$2.34M | -$2.34M |
| 有效稅率 | -- | -- | -- | -- |
常見問題
風險提示
股價可能大幅波動，短時間內可能出現顯著漲跌。 數位資產與衍生性商品交易可能涉及槓桿、流動性等額外風險。 本頁內容僅供參考，不構成任何投資建議。 產品可用性與訪問可能因地區及適用法規而異。